scholarly journals Low Serum Levels of Alpha1 Anti-trypsin (α1-AT) and Risk of Airflow Obstruction in Non-Primary α1-AT-Deficient Patients with Compensated Chronic Liver Disease

2015 ◽  
Vol 21 ◽  
pp. 1194-1199
Author(s):  
Nayeli Gabriela Jiménez-Saab
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Airflow Obstruction ◽  
Serum Levels ◽  
Chronic Liver ◽  
Low Serum

Reduced Serum Somatomedin Activity in Patients with Chronic Liver Disease

1974 ◽  
Vol 47 (4) ◽  
pp. 359-366 ◽  
Author(s):  
A. Wu ◽  
D. B. Grant ◽  
Judy Hambley ◽  
A. J. Levi
Keyword(s):  
Growth Hormone ◽  
Alkaline Phosphatase ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Severe Disease ◽  
Chronic Liver ◽  
Hormone Deficiency ◽  
Factor Activity ◽  
Important Site ◽  
Low Serum

1. Somatomedin (SM; sulphation factor) activity was estimated by a chick-cartilage assay in fasting sera from twenty-one patients with chronic liver disease. 2. Low SM values were found in nine out of the ten patients with cirrhosis and in two other patients, one with hepatofibrosis and one with hepatoma. 3. In general, the lowest serum SM activities were found in those patients with the most severe disease and significant correlations were found between serum SM and serum albumin, alkaline phosphatase and bilirubin. 4. Growth hormone was also measured in the samples and concentrations above 10 units/ml were found in seven patients, all of whom had reduced serum SM activities. 5. These findings indicate that low serum SM activity in liver disease is not related to growth hormone deficiency and suggest that the liver may be an important site for SM synthesis in man.

scholarly journals Serum levels of anti-heat shock protein 27 antibodies in patients with chronic liver disease

2020 ◽  
Vol 26 (1) ◽  
pp. 151-157
Author(s):  
Gabriella Gruden ◽  
Patrizia Carucci ◽  
Federica Barutta ◽  
Davina Burt ◽  
Arianna Ferro ◽  
...  
Keyword(s):  
Liver Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Chronic Liver

scholarly journals Biomarkers of Angiogenesis in Hepatocellular Carcinoma: A Novel Sunshine Road

2021 ◽  
Author(s):  
Krizia Pocino ◽  
Cecilia Napodano ◽  
Gabriele Ciasca ◽  
Mariapaola Marino ◽  
Nicoletta De Matthaeis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Venous Blood ◽  
Serum Levels ◽  
Chronic Liver ◽  
Number Of Factors ◽  
Measurement Results ◽  
Before And After

Background: Hepatocellular carcinoma (HCC) is a global health problem associated with chronic liver disease. The pathogenesis of chronic liver disease varies according to the underlying etiological factor, although in most cases it develops from a liver cirrhosis. The worsening progression of liver disease is accompanied by pathological angiogenesis, which is a prerequisite that favors the development of HCC. The aim of this study is to evaluate the clinical utility of circulating angiogenic markers VEGF, Ang-1, Ang-2, the Angiopoietin receptor (Tie1/2), HGF and PECAM-1 to screen early onset patients and to follow the evolution of HCC. Materials and Methods: We enrolled 62 patients; 33 out of 62 subjects were diagnosed for HCC and 29/62 for liver cirrhosis of different etiology without signs of neoplasia. Patients underwent venous blood sampling before and after treatments for VEGF, Ang-1, Ang-2, Tie1, Tie2, HGF and PECAM-1 measurement. Results: Ang-1 and Ang-2 are detectable not only in patients already suffering from HCC but also in cirrhotic patients without signs of cancer. Patients with HCC show higher HGF concentrations than patients with cirrhosis. A significant reduction in serum levels of Ang-2, Ang-2/Ang-1 and Ca 19-9 after DAAs therapy was observed. Moreover, VEGF levels were increased after treatment of HCC. Conclusion: The preliminary study here presented confirms that the mechanism of tumor angiogenesis is very complex and involves a very large number of factors. The integration of different methodologies and multi-marker algorithms is likely to emerge for the early diagnosis of HCC and the monitoring of the risk of relapse.

scholarly journals Carbohydrate 19.9 Antigen Serum Levels in Liver Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaetano Bertino ◽  
Annalisa Maria Ardiri ◽  
Giuseppe Stefano Calvagno ◽  
Giulia Malaguarnera ◽  
Donatella Interlandi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver ◽  
Neoplastic Disease ◽  
Prospective Longitudinal Study ◽  
Ca 19.9 ◽  
Prospective Longitudinal

Background.Carbohydrate 19.9 antigen (CA19.9) has been used in the diagnosis and followup of gastrointestinal tumours. The aim of this prospective longitudinal study was the evaluation of CA19.9 levels in patients with chronic hepatitis and hepatic cirrhosis hepatitis C virus and B virus correlated.Materials and Methods. 180 patients were enrolled, 116 with HCV-related chronic liver disease (48% chronic hepatitis, 52% cirrhosis) and 64 with HBV-related chronic liver disease (86% chronic hepatitis, 14% cirrhosis). Patients with high levels of CA19.9 underwent abdominal ecography, gastroendoscopy, colonoscopy, and abdominal CT scan.Results.51.7% of patients with HCV-related chronic liver disease and 48.4% of those with HBV-related chronic liver disease presented high levels of CA19.9. None was affected by pancreatic or intestinal neoplasia, cholestatic jaundice, or other diseases potentially able to induce Ca19.9 elevations. CA19.9 levels were elevated in 43.3% of HCV chronic hepatitis, in 56.3% of HCV cirrhosis, in 45.1% of HBV chronic hepatitis, and in 58% of HBV cirrhosis.Conclusions.CA19.9 commonly increases in the serum of patients with chronic viral hepatitis. Elevation of CA 19.9 is not specific for neoplastic disease and is related to the severity of fibrosis and to the viral aetiology of hepatitis.

Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease

2002 ◽  
Vol 22 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Patrick Schöffski ◽  
Frank Tacke ◽  
Christian Trautwein ◽  
Michael Uwe Martin ◽  
Martin Caselitz ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Chronic Liver
Sign in / Sign up

Export Citation Format

Share Document